EICHOR ● Recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Condition: Relapsed or Refractory Hematologic Malignancies · Sponsor: Vanda Pharmaceuticals

PhasePhase 1

Planned participants42

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

This description comes directly from the study's public registry record.

Talk to the study team

Vanda Pharmaceuticals · 202-734-3400 · clinicaltrials@vandapharma.com

Always discuss trial participation with your own doctor first.

Locations (11)

Vanda Investigational Site	Washington D.C., District of Columbia, United States	Withdrawn
Vanda Investigational Site	Lafayette, Indiana, United States	Completed
Vanda Investigational Site	Hackensack, New Jersey, United States	Withdrawn
Vanda Investigational Site	Seattle, Washington, United States	Completed
Vanda Investigational Site	Biała Podlaska, Poland	Recruiting
Vanda Investigational Site	Katowice, Poland	Recruiting
Vanda Investigational Site	Krakow, Poland	Completed
Vanda Investigational Site	Opole, Poland	Recruiting
Vanda Investigational Site	Skorzewo, Poland	Completed
Vanda Investigational Site	Warsaw, Poland	Recruiting
Vanda Investigational Site	Wroclaw, Poland	Completed

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →